Lv3
250 积分 2022-04-11 加入
Insights Into Vepdegestrant (ARV‐471): The First‐in‐Class Estrogen Receptor Proteolysis‐Targeting Chimera Approaching Food and Drug Administration Approval for Breast Cancer
16天前
已完结
Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease
23天前
已完结
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial
24天前
已完结
Trends in First‐in‐Human Studies for Intrathecal Antisense Oligonucleotides: Insights From 2010 to 2024
1个月前
已完结
LRRK2-targeting antisense oligonucleotide in Parkinson’s disease: a phase 1 randomized controlled trial
1个月前
已完结
Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series
1个月前
已完结
Tau Silencing by siRNA in the P301S Mouse Model of Tauopathy
1个月前
已完结
Discovery of AZD9750, an Orally Bioavailable Androgen Receptor Degrader for the Treatment of Prostate Cancer
1个月前
已完结
Preclinical translational physiologically based pharmacokinetic modeling for predicting human pharmacokinetics of proteolysis targeting chimeras: Case studies of vepdegestrant (ARV-471) and bavdegalutamide (ARV-110)
1个月前
已完结
Radioactive ADME Demonstrates ARV-110’s High Druggability Despite Low Oral Bioavailability
1个月前
已完结
皖公网安备34019202002308
